Monomorphic ventricular arrhythmias (MMVA) are not uncommon in athletes, 1,2 yet their presence appropriately raises concern among practitioners for possible increased risk of sudden cardiac death 
Clinical Arrhythmias
Interestingly, while idiopathic PVCs are often thought to be sympathetically mediated, there appears to be variability in the circadian distribution of PVC occurrence among patients. In a recent study of 101 consecutive unselected patients with frequent monomorphic PVCs referred for radiofrequency catheter ablation (RFA), 50.5% were found to have fast heart rate-dependent PVCs (more PVCs occurred at higher heart rates), whereas 9.9% had slow heart rate-dependent PVCs (more PVCs at lower heart rates). 9 No correlation between heart rate and PVC frequency was seen in the rest of the patients (39.6%). However, the circadian variability of PVCs in athletes has not been specifically studied and further data is needed to determine how different subtypes of PVCs/VT should be managed in athletes.
Evaluation
The initial diagnosis of MMVA in athletes may present in a variety of ways, including incidental detection on screening ECGs or after workup performed for symptoms such as palpitations. While most of these arrhythmias are likely to be benign, it is crucial to identify features that may be suggestive of underlying structural heart disease, warranting not only further workup but also potentially restriction from sports activity or competition. Beyond the routine history and physical examination that should be performed in all patients presenting with MMVA, important features to assess in athletes include arrhythmia frequency, response of the arrhythmia to exercise and electrocardiographic patterns ( Figure 1 ).
Clinical Assessment
While some athletes who are referred for evaluation of MMVA may be asymptomatic with an incidental finding of irregular heartbeat, 3, 4, 8 it is imperative to perform a detailed history to identify any concerning symptoms that the athlete may not otherwise mention unprompted. Specific symptoms to inquire about include palpitations, light-headedness, dizziness/presyncope, syncopal episodes, typical and atypical chest pain, dyspnoea that is sudden in onset or out of proportion to the degree of exercise, sudden fatigue, nausea, abdominal pain, or decreased exercise performance. Furthermore, family history should be queried for sudden death, syncope, or known cardiac disease, and basic laboratory tests -including a chemistry panel and thyroid function tests -should be performed to assess for possible contributions from electrolyte or endocrine abnormalities.
In addition to the physical exam, non-invasive studies that should be performed in athletes with MMVA are a 12-lead ECG, ambulatory ECG monitor (i.e. 24-hour Holter or 2-4 week event monitor), exercise stress testing and a transthoracic echocardiogram. 10 On the 12-lead ECG, the most recent version of the international recommendations on ECG interpretation in athletes should be used to identify abnormal findings, 11 which may be suggestive of pathologies (e.g. HCM and ARVC) that can predispose an athlete to MMVA. 12 Prior ECGs should be reviewed when available, and it may also be useful to obtain serial ECGs. It is also important to differentiate normal variants associated with different racial groups, such as early repolarisation seen in athletes of Afro-Caribbean descent where the ECG commonly shows elevated ST segments with upward concavity followed by negative T wave in V2-V4. 13 The exercise stress testing protocol should be based on maximal effort, not a target heart rate, and attempts should be made to replicate the level and form of exercise achieved in the athlete's sport. 1 The findings on these initial studies may prompt further evaluation, which may include but are not limited to coronary computed tomographic angiography and cardiac MRI.
Arrhythmia Frequency/Burden
The frequency/burden of PVCs/VT can be quantified by ambulatory 16 Interestingly, the sensitivity analyses found that only PVCs seen during the recovery phase of stress testing were associated with adverse outcomes.
Notably, these studies did not focus on athletes.
Electrocardiographic Patterns in Risk Stratification
Attempts to localise the origin of the PVC/VT may be helpful for 
Differential Diagnosis
Age has a strong influence on the differential diagnosis: older athletes (>35 years) are more likely to have atherosclerotic coronary artery disease (CAD) and ischaemic heart disease as an aetiology, whereas younger athletes (<35 years) are more likely to have congenital abnormalities, such as anomalous origin of a coronary artery, familial cardiomyopathy or a genetic predisposition to arrhythmia. Clinical Arrhythmias was found to be the most common structural cardiovascular cause of death, followed by anomalous origin of the coronary arteries. 18 A more recent 10-year study from Australia similarly found that a familial cardiomyopathy (HCM or ARVC) contributed to approximately 33% of sport-related SCD in children, 19 and an analysis of a UK registry found that myocardial disease (including left ventricular hypertrophy and fibrosis, HCM and ARVC) accounted for 40% of SCD in athletes. 20 Interestingly, HCM was found to be a more common cause of SCD in male athletes, while anomalous origin of the coronary arteries was the more common cause in female athletes. 21 However, the SCD reported in studies of patients with HCM is often related to polymorphic VT/VF, although they can also present with MMVA.
In older athletes with MMVA, atherosclerotic CAD should be considered, as it is the most common aetiology of sport-related SCD in this group, presumably due to ischaemic scar-related VA. 19 Other structural pathologies that can lead to MMVA in athletes of any age include arrhythmogenic inflammatory cardiomyopathy (including sarcoidosis and myocarditis) 22, 23 and valvular abnormalities (e.g. mitral valve prolapse).
24,25
Electrical Heart Disease While structural heart disease needs to be evaluated in athletes with MMVA, the most common finding in athletes who experienced SCD is a structurally normal heart, 26 and the most common cause of SCD in children and adolescent athletes is sudden arrhythmic death syndrome (SADS). 20 Presumably, SADS is because of undiagnosed inherited arrhythmia disorders, such as ion channelopathies. 27 These channelopathies include long QT syndrome, Brugada syndrome and catecholaminergic polymorphic ventricular tachycardia, but more commonly manifest as polymorphic VA and are thus outside of the scope of this review on MMVA.
Management
The management of any athlete with known or possible cardiovascular Athletes found to have structural heart disease or evidence of myocarditis should be advised to restrict themselves to playing low intensity (Class IA) sports, such as bowling and golf ( Figure 4 ). In particular, while expert opinion suggests that those with myocarditis may potentially be able to return to higher-intensity sports after evaluation for complete resolution of their condition, 1, 28 athletes with a diagnosis of ARVC should be counselled extensively on the importance of refraining from strenuous exercise indefinitely, as exercise in these patients is associated with a high risk of a lethal VT. [29] [30] [31] High-intensity exercise, independent of exercise duration, increases risk in patients with ARVC, 32 and exercise restriction has indeed been found to reduce VT frequency. 33 Athletes without overt ARVC, but who have a desmosomal mutation associated with ARVC, are at increased risk of developing ARVC, heart failure, and/or lethal VT with endurance and/ or frequent exercise. 34 These athletes should also be counselled to refrain from endurance exercise and high-intensity sports (above Class IA), but can likely still safely adhere to the AHA's minimal exercise recommendations (450 to 750 metabolic equivalent-minutes weekly). 35 Interestingly, it has been reported that high-intensity endurance exercise itself may result in ARVC-like pathology, including an increased risk of VT, without any detected genetic mutation ('gene-elusive'). [36] [37] [38] In addition, a recent study found a distinct pattern of isolated subepicardial RVOT scar associated with MMVA in high-level endurance athletes that is amenable to RFA. 39 However, little is known about the potential need for post-ablation exercise limitations in this patient population. Further, a small study of seven asymptomatic athletes with extensive subepicardial late gadolinium enhancement on cardiac MRI found that six of the seven developed symptomatic VT or progressive LV dysfunction. 40 The aetiology of the subepicardial scar was unknown in these athletes, and this study supports comprehensive evaluation and close follow-up in those athletes found to have myocardial fibrosis on cardiac MRI. 
Prescribed Deconditioning
In athletes without structural or electrical heart disease, prescribed periods of deconditioning (ranging from 12-24 weeks) have been shown to reduce the frequency of MMVA. 6 The beneficial effects of periods of deconditioning on frequency reduction appear to persist after a resumption of intensive training, when compared with the MMVA frequency prior to deconditioning. 41 However, in practice, athletes are often reluctant to participate in deconditioning periods.
Reassuringly, one study assessed 120 athletes with no obvious structural heart disease found to have a modest burden of PVCs (>100/24 hours) on routine pre-participation screening. 42 Continued sports activity in these athletes did not result in any deaths or development of overt heart disease, and overall modest PVC burden actually decreased over the median follow-up period of 84 months.
Thus, as long as there is no evidence of overt structural or electrical heart disease, deconditioning is an optional recommendation for many athletes with MMVA.
Medical Management
In symptomatic athletes, medical therapy can be considered to reduce symptoms and MMVA frequency. For athletes with symptomatic PVCs or a high PVC burden, beta-blocker therapy can be effective at reducing PVC frequency, and the ESC recommends beta-blockers as first-line medical therapy for the treatment of MMVA. 43 Additionally, beta-blockers can be considered for athletes with NSVT induced by exercise, and documentation of resolution of NSVT with exercise on beta-blocker therapy is required before an athlete can be cleared to return to competitive sport participation. For athletes with idiopathic MMVT, medical therapy can be considered if RFA is not possible or not desired, 45, 46 and the location of VT origin can be influential in guiding therapy. For instance, fascicular VT has been found to be responsive to the non-dihidropyridine calcium channel blocker verapamil, as well as beta-blockers. For outflow tract VT, class IC and class III antiarrhythmic medications are more effective than beta-blockers or calcium channel blockers, and can be considered as long as there is no evidence of structural heart disease. 46 However, the side effect profiles of antiarrhythmic medications need to be strongly considered prior to initiation in any athlete and beta-blockers are usually the first choice given the safety profile.
Radiofrequency Catheter Ablation
Many athletes, particularly younger ones, are reluctant to take medications because of concerns about their side effects and their possible impact on athletic performance. Fortunately, RFA of MMVT -previously limited to experienced academic centres -is now being increasingly performed internationally as more cardiac electrophysiologists gain advanced training in the procedure. 47 For athletes with symptomatic PVCs, RF ablation of PVCs may be considered if the PVCs are refractory to medications or if the athlete is unable or unwilling to take medications. 1 In contrast to medications, RFA can be curative of MMVAs. In fact, for PVCs with an RVOT origin, RFA was found to be more effective than antiarrhythmic drug therapy in preventing recurrence, 48 and a multi-centre study found RFA to have an 84% acute success rate with a low complication rate (2.4% major complications and 2.8% minor complications). 49 Complications were most commonly related to vascular access, but rare complications including cardiac tamponade and atrioventricular block can occur.
Notably no procedure-related stroke or deaths were seen in the 1,185
patients included in the study. 49 Furthermore, given the association of PVC frequency with an increased risk of heart failure (PVC-induced cardiomyopathy), 50 it is reasonable to consider RFA in athletes with a high PVC burden and/or a reduction in systolic function due to PVCs. 43 RFA of PVCs originating from the LVOT, aortic cusp, or epicardial origin should only be undertaken at experienced centres. For athletes with idiopathic, monomorphic sustained VT, RFA is also a reasonable therapeutic option.
1
In patients with MMVT associated with structural heart disease, such as ARVC and HCM, RFA can be considered, particularly if they are highly symptomatic or are experiencing frequent ICD therapies. A recent retrospective study of VT ablation in patients with non-ischaemic cardiomyopathy found that the outcomes of VT ablation differed based on the underlying etiology. 51 Patients with ARVC had the highest VT-free survival 1 year after RFA (82%), while patients with HCM had a relatively higher rate of VT recurrence after ablation. In another recent study focused on patients with ARVC VT, RF ablation was associated with similar outcomes compared to drug therapy, although combined epicardial-endocardial RF ablation resulted in lower VT recurrence compared with an endocardial alone approach. 52 Similarly, in a small, highly selected group of patients with MMVT associated with HCM, combined epicardial-endocardial RFA was effective at preventing recurrence of ICD shocks in 78% of patients at a median follow-up of 37 months. 53 Thus, RFA can be an effective option for select patients with ARVC and HCM. However, given the presence of structural heart disease, RFA therapy does not allow for return to athletic competition, even if successful, as the procedure may eliminate the clinical arrhythmia but does not resolve the underlying pathology and future development of new VT circuits is possible.
Device Implantation
The decision to implant an ICD in athletes is a particularly challenging one, as it may impact their ability to continue competition in their chosen sports. 54 Additionally, potential complications of ICDs include inappropriate shocks, device-related infections and lead failure. In particular, with transvenous ICD systems, repetitive arm motion during athletic activity may result in lead dislodgement with resulting sensing failure or in lead fracture and inappropriate shocks. 55 The recently available subcutaneous ICD may have a lower risk of lead malfunction. 56 The recommendations for ICD implantation in athletes follow the same guideline recommendations for primary and secondary prevention in the general population. 
Clinical Perspective
• MMVA, including premature ventricular complexes as well as non-sustained and sustained VT, are not uncommon in athletes and always raise concern about whether an athlete can continue to participate in competitive sports.
• Initial assessment includes a comprehensive history and physical examination and review of all available ECGs.
• Identifying high-risk features, particularly response to maximal exercise testing and presence of structural heart disease, is critical to determine safety of continued competitive sport participation.
• Echocardiography and frequently cardiac MRI are required to evaluate for structural heart disease, as certain conditions (i.e. ARVC, HCM) pose an elevated risk of sudden cardiac death during competition.
• Treatment options include observation and monitoring, exercise restriction, medical therapy, and interventions such as RFA and ICD implantation.
